TY - JOUR
T1 - p16INK4a status and response to induction low-dose fractionated radiation in advanced head and neck cancer
AU - Silver, Natalie L.
AU - Arnold, Susanne M.
AU - Gleason, John F.
AU - Kudrimoti, Mahesh
AU - Brill, Yolanda
AU - Dressler, Emily V.
AU - Valentino, Joseph
N1 - Publisher Copyright:
© The Author(s) 2015.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objective: To evaluate the impact of p16INK4a (p16) expression on clinical efficacy of induction low-dose fractionated radiation therapy (LDFRT) with concurrent chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Study Design: Historical cohort study. Setting: Tertiary medical center. Methods: A total of 66 Patients with locally advanced SCCHN were enrolled in 2 clinical trials using paclitaxel, carboplatin, and concurrent LDFRT induction therapy. Patients were evaluated for response to induction by a multidisciplinary team and then were given definitive treatment. Adequate tissue samples from the pretreatment biopsies of 42 individuals were identified and analyzed for p16 expression. Expression was correlated with clinical outcomes. Results: Of 42 tumors, 15 (35.7%) were positive for p16. Patients with p16-positive tumors had improved response to induction, but this was not statistically significant (P = .06). Five-year overall survival was 80% in p16-positive patients and 58% in p16-negative patients (P = .025). Conclusions: p16 Expression affects treatment response in patients treated with induction LDFRT with concurrent chemotherapy. This is similar to results reported for standard induction chemotherapy.
AB - Objective: To evaluate the impact of p16INK4a (p16) expression on clinical efficacy of induction low-dose fractionated radiation therapy (LDFRT) with concurrent chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Study Design: Historical cohort study. Setting: Tertiary medical center. Methods: A total of 66 Patients with locally advanced SCCHN were enrolled in 2 clinical trials using paclitaxel, carboplatin, and concurrent LDFRT induction therapy. Patients were evaluated for response to induction by a multidisciplinary team and then were given definitive treatment. Adequate tissue samples from the pretreatment biopsies of 42 individuals were identified and analyzed for p16 expression. Expression was correlated with clinical outcomes. Results: Of 42 tumors, 15 (35.7%) were positive for p16. Patients with p16-positive tumors had improved response to induction, but this was not statistically significant (P = .06). Five-year overall survival was 80% in p16-positive patients and 58% in p16-negative patients (P = .025). Conclusions: p16 Expression affects treatment response in patients treated with induction LDFRT with concurrent chemotherapy. This is similar to results reported for standard induction chemotherapy.
KW - Chemotherapy
KW - Head and neck squamous cell carcinoma
KW - Human papillomavirus
KW - Induction
KW - Low-dose
KW - P16
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=84942626653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942626653&partnerID=8YFLogxK
U2 - 10.1177/0003489415579220
DO - 10.1177/0003489415579220
M3 - Article
C2 - 25810339
AN - SCOPUS:84942626653
SN - 0003-4894
VL - 124
SP - 714
EP - 720
JO - Annals of Otology, Rhinology and Laryngology
JF - Annals of Otology, Rhinology and Laryngology
IS - 9
ER -